中药配合支气管动脉灌注化疗治疗非小细胞肺癌的临床观察

目的：探讨中药配合支气管动脉灌注化疗（BAIC）治疗肺癌的疗效。方法：中晚期非小细胞肺部（NSCLC）76例，随机A、B两组，A组39例为BAIC加中药治疗组，B组37例为单纯BAIC组。观察比较两组近期疗效、远期生存率、临床主要症状变化、生存质量及外周血象变化情况。结果：治疗后稳定加有效率（CR＋PR＋NC）A、B组分别为92．31％、70．275，组间比较差异有显著性（P＜0．05）。0．5、1、2年生存率A组分别为79．49％、56．41％、51．28％；B组分别为72．97％、51．35％、24．32％；2掉生存率A组优于B组（P＜0．05）。在改善临床症状、卡氏评分、增加体重，以及对治疗后外周血象变化的改善方面，A组患者比B组更明显。结论：中药配合BAIC可以提高BAIC效果。

Clinical Observation on Treatment of Non-Small Cell Lung Cancer with Chinese Herbal Medicine Combined with Bronchial Arterial Infusion Chemotherapy

Objective: To explore the effect of treatment for non-small cell lung cancer (NSCLC) with Chinese herbal medicine (CHM) combined with bronchial arterial infusion chemotherapy (BAIC). Methods: Patients with moderate or advanced NSCLC were randomly divided into two groups, the 39 patients in the treated group treated with CHM plus BAIC therapy and 37 in the control group treated with BAIC alone. The short-term therapeutic effect, long-term survival rate, changes of clinical principal symptoms, quality of life and peripheral blood pictures in the two groups were observed and compared. Results: After treatment the rate of CR PR NC in the treated and the control group was 92.31% and 70.27% respectively, the inter-group comparison showed a significant difference (P<0.05). The 0.5-, 1-and 2-year survival rate in the treated group was 79.49%, 56.41% and 51.28% respectively and in the control group, 72.97%, 51.35% and 24.32% respectively. The 2-year survival rate in the former was better than that in the latter (P<0.05). Moreover, the improvement of clinical symptoms, Karnofsky scoring, body weight and peripheral blood picture in the treated group was superior to that in the control group. Conclusion: Therapeutic effect of BAIC could be enhanced by combining it with CHM.